Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Dutch biopharmaceutical company Crucell has announced a non-exclusive Star research license agreement with Bioceros.
Subscribe to our email newsletter
The license agreement with the Netherlands based company Bioceros covers the production of monoclonal antibodies. Financial details of the agreement were not disclosed.
Star technology is a production technology that is particularly useful for the production of recombinant human antibodies and proteins. It has a potentially broad application and is said to be effective for production of antibodies and proteins on mammalian cell lines such as Crucell’s PER.C6 human cell technology and the widely used Chinese hamster ovary cell line.